Skip to content

Probiotic bacteria for work-related stress

Efficacy of Lactobacillus reuteri PBS072 and Bifidobacterium breve BB077 in the prevention and treatment of work-related stress symptoms: a cross-over randomized trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN15033071
Enrollment
40
Registered
2021-04-29
Start date
2021-03-25
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Work-related stress Mental and Behavioural Disorders Other physical and mental strain related to work

Interventions

A cross-over clinical study will be carried out to evaluate the efficacy of the probiotic formulation composed of 2 × 10(9) CFU Lactobacillus reuteri PBS072 and 2 × 10(9) CFU Bifidobacterium breve BB0

Sponsors

University of Calabria
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults aged between 18 and 65 in good health 2. Willing to use only the products to be tested throughout the study period 3. Willing not to use similar products that could interfere with the product to be tested 4. Willing not to change normal daily routine (e.g. lifestyle, physical activity, etc)

Exclusion criteria

Exclusion criteria: 1. Subjects with known or suspected sensitization to one or more ingredients of the formulation in question 2. Subjects unable to communicate or collaborate with the investigator due to language problems, intellectual disability, or impaired brain function 3. People suffering from psychiatric disorders such as schizophrenia, or psychotic disorders such as bipolar disorder or substance use disorder 4. Use of herbal remedies or psychotropic drugs intended for depression taken in the last 2 weeks before baseline or during the study 5. Receive counseling or psychological therapy at the beginning or during the study 6. Participation in any clinical trial in the previous 3 months prior to baseline 7. Subjects who plan to take antibiotics during the treatment period

Design outcomes

Primary

MeasureTime frame
Sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) at baseline and after 30 days

Secondary

MeasureTime frame
Subjective mood measured using the Profile of Mood States (POMS) at baseline and after 30 days

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026